Revert L

Prognostic value of spontaneous hyponatremia in cirrhosis with ascites

AbstractSpontaneous hyponatremia in cirrhosis with ascites is generally considered to be due to an impaired renal ability to excrete free water, to be a contraindication of diuretics, and to be a bad prognostic sign. These concepts are reviewed in this paper. 55 cirrhotics with ascites were divided into three groups. Group I consisted of 13 patients with hyponatremia and very low free-water clearance (

Systemic involvement of dialysis-amyloidosis

C_{H_2 O}

Visceral Involvement of Dialysis Amyloidosis

, 0.07±0.26 ml/min). These patients also had poor renal function: low inulin clearance (CINU, 40.6±25.9 ml/min) and paraamino-hippurate clearance (CPAH, 383±275 ml/min). Group II consisted of 8 patients who also had hyponatremia.

Pathological fractures in patients who have amyloidosis associated with dialysis. A report of five cases.

C_{H_2 O}

Ocular and Auditory Toxicity in Hemodialyzed Patients Receiving Desferrioxamine

, CINU, and CPAH in these patients were fairly high: 5.85±1.53 ml/min, 85.7±26.2 ml/min, and 651±294 ml/min. These values are similar to those of the 34 patients without hyponatremia who make up Group III: (6.37±4.27 ml/min, 94.7±33.1 ml/min, and 598±199 ml/min). Hyponatremia in Group I could be related to the impaired free-water clearance. The mechanism of hyponatremia in Group II patients is not clear. Patients with hyponatremia and low CINU and CPAH had a negative response to diuretics and a poor prognosis. Patients with hyponatremia but with relatively good renal function had a good prognosis, similar to Group III patients. They responded to diuretics with no worsening of their hyponatremia.

Angiotensinogen gene M235T and T174M polymorphisms in essential hypertension: relation with target organ damage.

Summary. From January 1982 to December 1993, 30 patients with multiple myeloma (MM) required haemodialysis (HD) at our institution. The subgroup of 20 patients who survived more than 2 months on HD is the subject of this study. Four patients were already on HD, due to previous nephropathy, when MM was diagnosed. 13 patients presented with acute renal failure and were on dialysis from the time of diagnosis. The remaining three cases developed renal failure later in the course of the disease. The objective response rate was 40% (8/20). Only two patients could discontinue HD (one had a late partial recovery and one received a kidney graft). Mean hospitalization per year was 19.3 d. The subgroup of patients who survived < 1 year spent a mean of 38.3 d in hospital. Whereas in the subgroup with a survival > 1 year mean hospitalization days was 9.6 (P < 0.001). The median survival was 20 months and six patients survived for > 3 years. In summary, patients with MM and severe renal failure who survive the first 2 months on dialysis have an objective response rate to chemotherapy of 40% and a median survival of almost 2 years, with 30% long‐term survivors.